<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:21:10Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5770914" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5770914</identifier>
        <datestamp>2018-01-19</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="protocol">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5770914</article-id>
              <article-id pub-id-type="pmcid">PMC5770914</article-id>
              <article-id pub-id-type="pmc-uid">5770914</article-id>
              <article-id pub-id-type="pmid">29288190</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2017-019474</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2017-019474</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Surgery</subject>
                  <subj-group>
                    <subject>Protocol</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1737</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Can we <italic>S</italic>ave the rectum by watchful waiting or
<italic>T</italic>rans<italic>A</italic>nal microsurgery following (chemo)
<italic>R</italic>adiotherapy versus <italic>T</italic>otal mesorectal excision
for early <italic>RE</italic>ctal <italic>C</italic>ancer (STAR-TREC study)?:
protocol for a multicentre, randomised feasibility study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rombouts</surname>
                    <given-names>Anouk J M</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-57705939" contrib-type="author">
                  <name>
                    <surname>Al-Najami</surname>
                    <given-names>Issam</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Abbott</surname>
                    <given-names>Natalie L</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Appelt</surname>
                    <given-names>Ane</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                  <xref ref-type="aff" rid="aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Baatrup</surname>
                    <given-names>Gunnar</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bach</surname>
                    <given-names>Simon</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bhangu</surname>
                    <given-names>Aneel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garm Spindler</surname>
                    <given-names>Karen-Lise</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff7">7</xref>
                  <xref ref-type="aff" rid="aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gray</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Handley</surname>
                    <given-names>Kelly</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kaur</surname>
                    <given-names>Manjinder</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kerkhof</surname>
                    <given-names>Ellen</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kronborg</surname>
                    <given-names>Camilla Jensenius</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Magill</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marijnen</surname>
                    <given-names>Corrie A M</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nagtegaal</surname>
                    <given-names>Iris D</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nyvang</surname>
                    <given-names>Lars</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff15">15</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Peters</surname>
                    <given-names>Femke P</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pfeiffer</surname>
                    <given-names>Per</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff16">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Punt</surname>
                    <given-names>Cornelis</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff17">17</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Quirke</surname>
                    <given-names>Philip</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sebag-Montefiore</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff19">19</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Teo</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff19">19</xref>
                  <xref ref-type="aff" rid="aff20">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>West</surname>
                    <given-names>Nick</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de Wilt</surname>
                    <given-names>Johannes H W</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <on-behalf-of>for STAR-TREC Collaborative Group</on-behalf-of>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Department of Surgery</institution>,
<institution>Radboud University Medical Centre</institution>, <addr-line content-type="city">Nijmegen</addr-line>, <country>The Netherlands</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Surgery</institution>,
<institution>Odense University Hospital</institution>, <addr-line content-type="city">Odense</addr-line>, <country>Denmark</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Radiotheraphy Trials Quality Assurance
Group</institution>, <institution>Velindre Cancer Centre</institution>, <addr-line content-type="state">Cardiff</addr-line>, <country>UK</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Leeds Institute of Cancer and
Pathology</institution>, <institution>University of Leeds</institution>, <addr-line content-type="city">Leeds</addr-line>, <country>UK</country></aff>
              <aff id="aff5"><label>5</label><institution>Leeds Cancer Centre, St. James’ University Hospital</institution>,
<addr-line content-type="city">Leeds</addr-line>, <country>UK</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Department of Surgery</institution>,
<institution>University Hospitals Birmingham</institution>, <addr-line content-type="city">Birmingham</addr-line>, <country>UK</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Department of Clinical Oncology</institution>,
<institution>Aarhus University Hospital</institution>, <addr-line content-type="city">Aarhus</addr-line>, <country>Denmark</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Department of Clinical Medicine</institution>,
<institution>Aarhus University</institution>, <addr-line content-type="city">Aarhus</addr-line>, <country>Denmark</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">Clinical Trial Services Unit</institution>,
<institution>University of Oxford</institution>, <addr-line content-type="city">Oxford</addr-line>, <country>UK</country></aff>
              <aff id="aff10"><label>10</label><institution content-type="department">Institue of Applied Health
Research</institution>, <institution>University of Birmingham Clinical Trials
Unit</institution>, <addr-line content-type="city">Birmingham</addr-line>,
<country>UK</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">Birmingham Clinical Trials Unit</institution>,
<institution>University of Birmingham</institution>, <addr-line content-type="city">Birmingham</addr-line>, <country>UK</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">Department of Radiotherapy</institution>,
<institution>Leiden University Medical Center</institution>, <addr-line content-type="city">Leiden</addr-line>, <country>The Netherlands</country></aff>
              <aff id="aff13"><label>13</label><institution content-type="department">Department of Clinical Oncology</institution>,
<institution>Aarhus University Hospital</institution>, <addr-line content-type="city">Aarhus</addr-line>, <country>Denmark</country></aff>
              <aff id="aff14"><label>14</label><institution content-type="department">Department of Pathology</institution>,
<institution>Radboud University Medical Centre</institution>, <addr-line content-type="city">Nijmegen</addr-line>, <country>The Netherlands</country></aff>
              <aff id="aff15"><label>15</label><institution content-type="department">Department of Medical Physics</institution>,
<institution>Aarhus University Hospital</institution>, <addr-line content-type="city">Aarhus</addr-line>, <country>Denmark</country></aff>
              <aff id="aff16"><label>16</label><institution content-type="department">Department of Oncology</institution>,
<institution>Odense University Hospital</institution>, <addr-line content-type="city">Odense</addr-line>, <country>Denmark</country></aff>
              <aff id="aff17"><label>17</label><institution content-type="department">Department of Medical Oncology</institution>,
<institution>Academic Medical Center</institution>, <addr-line content-type="city">Amsterdam</addr-line>, <country>The Netherlands</country></aff>
              <aff id="aff18"><label>18</label><institution content-type="department">Department of Pathology</institution>,
<institution>School of Medicine, University of Leeds</institution>, <addr-line content-type="city">Leeds</addr-line>, <country>UK</country></aff>
              <aff id="aff19"><label>19</label><institution content-type="department">Department of Clinical Oncology</institution>,
<institution>Leeds Radiotherapy Research Group, University of Leeds</institution>,
<addr-line content-type="city">Leeds</addr-line>, <country>UK</country></aff>
              <aff id="aff20"><label>20</label><institution content-type="department">Department of Clinical Oncology</institution>,
<institution>Leeds Cancer Centre, St James University Hospital</institution>,
<addr-line content-type="city">Leeds</addr-line>, <country>UK</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Professor Johannes H W de Wilt;
<email>star-trec@radboudumc.nl</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>28</day>
                <month>12</month>
                <year>2017</year>
              </pub-date>
              <volume>7</volume>
              <issue>12</issue>
              <elocation-id>e019474</elocation-id>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>9</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>20</day>
                  <month>10</month>
                  <year>2017</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Article author(s) (or their employer(s) unless otherwise
stated in the text of the article) 2017. All rights reserved. No commercial use is
permitted unless otherwise expressly granted.</copyright-statement>
                <copyright-year>2017</copyright-year>
                <license license-type="open-access">
                  <license-p>This is an Open Access article distributed in accordance with the terms of
the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2017-019474.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2017-019474.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2017-019474.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Total mesorectal excision (TME) is the highly effective standard treatment for
rectal cancer but is associated with significant morbidity and may be
overtreatment for low-risk cancers. This study is designed to determine the
feasibility of international recruitment in a study comparing organ-saving
approaches versus standard TME surgery.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>STAR-TREC trial is a multicentre international randomised, three-arm parallel,
phase II feasibility study in patients with biopsy-proven adenocarcinoma of the
rectum. The trial is coordinated from Birmingham, UK with national hubs in
Radboudumc (the Netherlands) and Odense University Hospital Svendborg UMC
(Denmark). Patients with rectal cancer, staged by CT and MRI as ≤cT3b (up
to 5 mm of extramural spread) N0 M0 can be included. Patients will be
randomised to either standard TME surgery (control), organ-saving treatment using
long-course concurrent chemoradiation or organ-saving treatment using short-course
radiotherapy. For patients treated with an organ-saving strategy, clinical
response to (chemo)radiotherapy determines the next treatment step. An active
surveillance regime will be performed in the case of a complete clinical
regression. In the case of incomplete clinical regression, patients will proceed
to local excision using an optimised platform such as transanal endoscopic
microsurgery or other transanal techniques (eg, transanal endoscopic operation or
transanal minimally invasive surgery). The primary endpoint of this phase II study
is to demonstrate sufficient international recruitment in order to sustain a phase
III study incorporating pelvic failure as the primary endpoint. Success in phase
II is defined as randomisation of at least four cases per month internationally in
year 1, rising to at least six cases per month internationally during year 2.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The medical ethical committees of all the participating countries have approved
the study protocol. Results of the primary and secondary endpoints will be
submitted for publication in peer-reviewed journals.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN14240288" specific-use="clinicaltrial pre-results">ISRCTN14240288</ext-link>, 20 October
2016. <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT02945566" specific-use="clinicaltrial pre-results">NCT02945566</ext-link>; Pre-results,
October 2016.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>rectal cancer</kwd>
                <kwd>chemoradiation</kwd>
                <kwd>TEM</kwd>
                <kwd>radiotherapy</kwd>
                <kwd>watchful waiting</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008363</institution-id>
                      <institution>Kræftens Bekæmpelse</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id>
                      <institution>KWF Kankerbestrijding</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id>
                      <institution>Cancer Research UK</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float" orientation="portrait">
              <caption>
                <title>Strengths and limitations of this study</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>This phase II study is the first study to randomise between the standard of care
in early rectal cancer (ie, total mesorectal excision surgery) and two
organ-saving strategies using (chemo)radiotherapy followed by selective transanal
microsurgery.</p>
                </list-item>
                <list-item>
                  <p>STAR-TREC study will show whether it is feasible to recruit enough patients for a
consecutive international large, multicentre randomised phase III trial.</p>
                </list-item>
                <list-item>
                  <p>The study design incorporates several adjustments in standard (chemo)radiation
therapy protocols intended to reduce treatment-related side effects associated
with organ-saving therapy.</p>
                </list-item>
                <list-item>
                  <p>Clinical nodal staging of rectal cancer is rather unreliable and patients with
false-negative nodal disease will be included in the study.</p>
                </list-item>
                <list-item>
                  <p>Experience with clinical judgement of a complete response is difficult and needs
to be monitored carefully with central reviewing during the study.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>The introduction of bowel cancer screening is associated with a significant increase in
the incidence of early-stage rectal cancer.<xref rid="R1" ref-type="bibr">1 2</xref>
Total mesorectal excision (TME) surgery is an effective oncological treatment for
early-stage rectal cancer, only 2% and 12% of patients experience local or distant
failure, respectively.<xref rid="R3" ref-type="bibr">3–5</xref> However,
standard surgery for rectal cancer requires permanent stoma formation in 10%–20%
of cases and temporary stoma formation in 60%–70%.<xref rid="R6" ref-type="bibr">6 7</xref> Many temporary stomas are not reversed.<xref rid="R8" ref-type="bibr">8 9</xref> Furthermore, TME surgery is associated with major morbidity
and mortality in a significant number of patients. Over 50% of all patients following
TME surgery experience faecal incontinence, whereas urinary problems and sexual
dysfunction are observed in 32%–80% of patients.<xref rid="R10" ref-type="bibr">10–14</xref> Another complication following TME
surgery is anastomotic bowel leakage which occurs in approximately 15% of patients.<xref rid="R15" ref-type="bibr">15</xref> In addition, quality-of-life studies show that
TME surgery is associated with persistently poor social role and body image.<xref rid="R12" ref-type="bibr">12 16–19</xref> Mortality following
TME surgery rises with age; the 6-month mortality following TME surgery is
2.0%–4.6% for young patients with rectal cancer and 9.0%–13.4% for elderly
patients (aged &gt;75 years).<xref rid="R20" ref-type="bibr">20–22</xref>
There are concerns that TME surgery, which evolved to treat locally advanced,
symptomatic tumours, may result in significant overtreatment of early screen-detected
tumours. An organ-preserving strategy may generate significantly less morbidity without
substantially compromising oncological outcomes. Promising outcomes have been reported
for (chemo)radiation therapy followed by watchful waiting or local excision.</p>
              <p>Habr-Gama’s group have notably published a watchful waiting approach to rectal
cancer. Of 265 patients with predominantly T3 rectal cancer treated with chemoradiation
therapy (CRT), 71 patients (27%) had a complete clinical response (cCR).<xref rid="R23" ref-type="bibr">23 24</xref> These patients did not have surgery and
after a mean follow-up of 57 months (range: 18–156), only two patients developed
local recurrence, one of which was successfully salvaged. A Dutch group then
prospectively selected patients with cCR for a watchful waiting strategy (n=21).<xref rid="R25" ref-type="bibr">25</xref> After a mean follow-up 25 months (±19
months), one patient had developed a local recurrence which was salvaged by surgery and
all other patients were alive without disease. In 2015, the effect of a radiation boost
after CRT was evaluated in a prospective observational Danish study. A watch and wait
policy was possible in 40 out of 51 included patients.<xref rid="R26" ref-type="bibr">26</xref> At 1 year, local recurrence occurred in 16% of 40 patients who
initially showed a cCR. Rectal bleeding was relatively frequent in this study during
follow-up perhaps relating to the higher radiotherapy doses that were used. However,
these results which combine high cCR rates and low local recurrence rates have not been
consistently replicated.<xref rid="R27" ref-type="bibr">27 28</xref> Furthermore,
CRT is associated with treatment-related morbidity and a mortality rate of
0.5%–1% should be considered.<xref rid="R29" ref-type="bibr">29</xref></p>
              <p>Another organ-saving treatment strategy is local excision instead of radical surgery.
Early rectal tumours may be locally excised through the anus with low morbidity and
mortality using transanal endoscopic microsurgery (TEM), allowing rectal-saving
treatment.<xref rid="R30" ref-type="bibr">30 31</xref> Morbidity and mortality
after local excision are much lower than after major resection. Morbidity associated
with TEM includes bowel perforation, (transitory) incontinence, wound infection and
local pain.<xref rid="R32" ref-type="bibr">32–34</xref> In a study of
5305 patients with early-stage rectal cancer, 30-day mortality after local excision was
found to be 0.5% compared with 2.4% in patients undergoing major resection (P=0.008).
Morbidity within 30 days of surgery was 4.4% in the local excision group versus 12.7% in
the major resection group (P&lt;0.001).<xref rid="R34" ref-type="bibr">34</xref>
However, the risk of non-radical resection after local excision is higher and the risks
of leaving behind microscopic lymph node metastases are a potential cause of local
failure.<xref rid="R5" ref-type="bibr">5 35</xref> The incidence of lymph node
metastasis ranges from 6% to 14% for T1 tumours, 17% to 23% for T2 tumours and 49% to
66% for T3 tumours.<xref rid="R36" ref-type="bibr">36</xref></p>
              <p>Combining radiotherapy with TEM could possibly lead to better outcomes because
radiotherapy can effectively treat microscopic mesorectal nodal metastases and
contribute to tumour downsizing.<xref rid="R37" ref-type="bibr">37 38</xref>
However, limited prospective evidence currently exists to guide the use of radiotherapy
and local excision as curative treatment for early rectal cancer. Lezoche <italic>et
al</italic> randomised 100 patients with T2N0 rectal cancer to CRTfollowed by
laparoscopic TME surgery or CRT and TEM with a 6–8 week interval to
surgery.<xref rid="R39" ref-type="bibr">39</xref> After a median follow-up of
9 years, local recurrence rates were 6% and 8% in the TME and TEM arms,
respectively. In a trial of 89 patients with unfavourable cT1N0, cT2N0 or borderline
cT2/3N0 tumours by Bujko <italic>et al</italic>, patients were given neoadjuvant
treatment with short-course radiation therapy (SCRT) or CRT prior to delayed local
excision.<xref rid="R40" ref-type="bibr">40</xref> No further treatment was offered
for good responders, whereas immediate TME surgery was recommended for all other
patients. Good responders had a 2-year local recurrence rate of 10%. Of the poor
responders, eight patients had a TME and none of this group had a recurrence, however,
18 declined or were unfit for TME, and this group had a 2-year local recurrence rate of
37%. This underlines that in high-risk or poor responding patients, neoadjuvant
radiotherapy followed by local excision is inadequate treatment.</p>
              <p>A study investigating chemoradiation therapy for rectal cancer in the distal rectum
followed by organ-sparing transanal endoscopic microsurgery (CARTS) was a non-randomised
phase II study that evaluated CRT followed by TEM in 55 patients with stage
T1–3N0 rectal cancer.<xref rid="R41" ref-type="bibr">41</xref> Clinical response
was assessed 6–8 weeks after completion of CRT and TEM was performed. Organ
saving was achieved in more than half of patients and 21 had ypT0 disease. Radiotherapy
consisted of 50 Gy in 25 fractions and capecitabine 825 mg/m<sup>2</sup> two
times per day was given for the same period 7 days per week. However, 42% of patients
developed at least grade 3 toxicity and there were two toxicity-related deaths. A
multicentre cohort study from the UK that employed SCRT with TEM after 10 weeks
demonstrated that 43/62 cases had either no or minimal residual disease following
radiotherapy.<xref rid="R42" ref-type="bibr">42</xref> None of these patients
experienced short-term pelvic relapse and treatment-related toxicity was low. The ACOSOG
Z6041 study, a single-arm phase II study, evaluated an oxaliplatin and capecitabine
concurrent chemotherapy schedule combined with 54 Gy of pelvic radiotherapy followed by
TEM for T2N0 rectal cancer.<xref rid="R43" ref-type="bibr">43</xref> Both radiotherapy
and chemotherapy schedules required reduction during the study due to acute toxicity.
Only 3 out of 79 evaluable patients experienced local failure as first event. TREC is a
phase II UK study evaluating the feasibility of randomising patients to receive either
organ-saving treatment with SCRT and TEM versus standard TME surgery. This study is due
to report in 2017 having completed minimum 2-year follow-up.</p>
              <p>In conclusion, several strategies can be followed to improve the quality of life of
patients with rectal cancer by aiming for organ preservation. However, all data so far
are derived from small phase II studies and many questions regarding the optimal
radiotherapy schedule and the optimal timing of evaluation remain. In addition,
prospective comparative data with radical surgery are not available. Therefore, there is
an urgent need for a randomised phase III trial to establish the risks, complication
rates and benefits of organ saving compared with standard radical surgery for
early-stage rectal cancer. The aim of STAR-TREC study is to assess the feasibility of
successfully recruiting to a large, multicentre randomised trial comparing radical
surgery versus organ saving treatment using (chemo)radiotherapy followed by
selective transanal microsurgery.</p>
            </sec>
            <sec id="s2">
              <title>Methods and analysis</title>
              <sec id="s2a">
                <title>Design</title>
                <p>STAR-TREC trial is a multicentre international randomised, three-arm parallel study
in patients with biopsy-proven adenocarcinoma of the rectum. The trial is coordinated
from Birmingham, UK with national hubs in Radboudumc (the Netherlands) and Odense
University Hospital Svendborg UMC (Denmark). Participants are currently being
recruited and enrolled; the first patient was enrolled in July 2017.</p>
                <p>The primary endpoints of STAR-TREC study (phase II) are defined as:<list list-type="order"><list-item><p>Year 1: Randomise at least four cases per month internationally (n=48).</p></list-item><list-item><p>Year 2: Randomise at least six cases per month internationally (n=72).</p></list-item></list></p>
                <p>The secondary endpoints of this phase II trial are:<list list-type="order"><list-item><p>Year 1: Can one international partner procure independent funding in year 1?
Successful international collaboration will be necessary to deliver a future
phase III study.</p></list-item><list-item><p>Year 1: Can one international partner open the study to recruit in year
1?</p></list-item><list-item><p>Efficacy of organ-preserving treatment arms on completion of phase II study:
Is the organ-saving rate &gt;50% at 12 months (following randomisation) in the
experimental arms?</p></list-item></list></p>
                <p>Additional outcome measures pertinent to a future phase III study examining the
safety and efficacy of organ saving versus standard surgery will also be
collected.</p>
                <sec id="s2a1">
                  <title>Safety</title>
                  <list list-type="bullet">
                    <list-item>
                      <p>accuracy of MRI in predicting STAR-TREC eligibility;</p>
                    </list-item>
                    <list-item>
                      <p>30-day and 6-month mortality;</p>
                    </list-item>
                    <list-item>
                      <p>surgical morbidity;</p>
                    </list-item>
                    <list-item>
                      <p>rate of tumour recurrence or regrowth within the bowel wall (experimental
arm);</p>
                    </list-item>
                    <list-item>
                      <p>rate of tumour recurrence within the mesorectum (experimental arm);</p>
                    </list-item>
                    <list-item>
                      <p>rate of distant metastases;</p>
                    </list-item>
                    <list-item>
                      <p>pelvic failure rate: expressed as a sum of the following: (1) unresectable
pelvic tumour, (2) cases requiring beyond TME surgery or (3) tumour
recurrence or regrowth ≤1 mm from the circumferential surgical
margin after TME surgery. This outcome measure will be pivotal in
challenging current clinical practice and it is our intention that it
becomes the primary endpoint in phase III;</p>
                    </list-item>
                    <list-item>
                      <p>bowel, bladder and sexual dysfunction (baseline and 12, 24 months
postrandomisation).</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2a2">
                  <title>Efficacy</title>
                  <list list-type="bullet">
                    <list-item>
                      <p>proportion of patients with/without a stoma at 30 days and
1 year;</p>
                    </list-item>
                    <list-item>
                      <p>histopathological assessment of tumour downstaging following radiotherapy
according to depth of tumour invasion and the incidence of other high-risk
features in comparison to non-irradiated (control) group;</p>
                    </list-item>
                    <list-item>
                      <p>proportion of patients identified by clinical and MRI assessment as suitable
for active monitoring;</p>
                    </list-item>
                    <list-item>
                      <p>conversion rates from organ saving to radical surgery;</p>
                    </list-item>
                    <list-item>
                      <p>disease-free survival;</p>
                    </list-item>
                    <list-item>
                      <p>quality of life (baseline and 12, 24 months postrandomisation);</p>
                    </list-item>
                    <list-item>
                      <p>overall survival.</p>
                    </list-item>
                  </list>
                </sec>
              </sec>
              <sec id="s2b">
                <title>Study population</title>
                <p>This is a hospital-based study. Centre eligibility depends on a Radiotherapy Trials
Quality Assurance which is a mixture of an approved departmental standard operating
procedure and successful contouring of a case using the new principles of mesorectal
irradiation. Candidates will generally be identified in the endoscopy suite following
referral for: (1) the investigation of new bowel symptoms, (2) as part of a personal
bowel surveillance programme or (3) through national bowel screening. Subjects will
then be referred on to either a colorectal surgeon or the colorectal cancer
multidisciplinary team (MDT) meeting. Eligibility will be confirmed at the MDT
meeting. The main inclusion and exclusion criteria for the trial are summarised in
<xref rid="T1" ref-type="table">table 1</xref>.</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Inclusion and exclusion criteria</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">Inclusion criteria</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">Exclusion criteria</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">1. Age &gt;16 years (UK), age
&gt;18 years (Netherlands and Denmark)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1. MRI node positive*</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">2. Biopsy-proven adenocarcinoma of the
rectum</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2. MRI extramural invasion present*</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">3. MRI T1–3b N0 M0 rectal tumour</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3. MRI-defined mucinous tumour</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">4. Multidisciplinary team meeting determines
that the following treatment options are all reasonable and
feasible:<list list-type="alpha-lower"><list-item><p>TME surgery,</p></list-item><list-item><p>Chemoradiation therapy,</p></list-item><list-item><p>Short-course chemoradiation therapy</p></list-item><list-item><p>TEM</p></list-item></list>
</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4. Mesorectal fascia threatened by tumour
(≤1 mm on MRI)</td>
                      </tr>
                      <tr>
                        <td valign="top" rowspan="5" align="left" colspan="1">5. Estimated creatinine clearance
&gt;50 mL/min</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5. Maximum tumour diameter &gt;40 mm;
measured from everted edges on sagittal MRI</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">6. Anterior tumour location above the
peritoneal reflection on MRI or endoscopic rectal ultrasound</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">7. No residual luminal tumour following
endoscopic mucosal resection</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">8. Prior pelvic radiotherapy</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">9. Regional or distant metastases</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>*Defined by protocol guidelines.</p>
                    </fn>
                    <fn id="tblfn2">
                      <p>TEM, transanal endoscopic microsurgery; TME, total mesorectal excision.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2c">
                <title>Study arms</title>
                <p>Patients will be randomised to either standard TME surgery (control), organ-saving
treatment using long-course concurrent CRT or organ-saving treatment using SCRT
(<xref ref-type="fig" rid="F1">figure 1</xref>). Patients allocated to TME surgery
will have a minimum of one abdominal CT scan and regular clinical follow-up will be
made according to national guidelines. In the two organ-saving arms, response
assessment will take place at 11–13 weeks from the start of
(chemo)radiotherapy and again at 16–20 weeks from start. Initial assessment at
11–13 weeks (MRI and endoscopy) will identify a small proportion of cases
where radiotherapy has had little or no impact on tumour dimensions. Non-responding
patients will be advised to convert to standard TME surgery. Individuals whose
tumours demonstrate a satisfactory response at this time point will be examined once
again at 16–20 weeks (endoscopy) to determine if a cCR has occurred. It is
anticipated that this interval between assessments will allow for additional tumour
regression and resolution of acute radiotherapy reactions, facilitating more precise
diagnosis of cCR. An active surveillance regime will be performed in the case of a
cCR. In the case of incomplete clinical regression, patients will progress to local
excision, see <xref ref-type="fig" rid="F1">figure 1</xref>. Representative
endoscopic images will be centrally reviewed during this feasibility stage to develop
a consistent approach to interpretation of the clinical assessment.</p>
                <fig id="F1" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Flow chart of the inclusion, randomisation and management of the study subjects
in STAR-TREC trial. APE, anterior perianal excision; CRT, chemoradiation
therapy; LAR, low anterior resection; SCRT, short-course radiation therapy;
TEM, transanal endoscopic microsurgery; TME, total mesorectal excision.</p>
                  </caption>
                  <graphic xlink:href="bmjopen-2017-019474f01"/>
                </fig>
                <p>All patients must be assigned to one of the three treatment groups by week 20:<list list-type="order"><list-item><p>Poor response assessed at 11–13 weeks—patient recommended to
convert to radical TME surgery.</p></list-item><list-item><p>cCR assessed at 16–20 weeks means that the bowel wall has reverted to
normal and patients are treated by watchful waiting.</p></list-item><list-item><p>Clinically satisfactory, yet incomplete tumour response at 16–20
weeks, meaning a 50% or more reduction of tumour size and the presence of
any residual mucosal or bowel wall abnormality suggestive of persisting
tumour, will prompt local excision by TEM.</p></list-item></list></p>
              </sec>
              <sec id="s2d">
                <title>Treatment regimen for organ-saving strategies</title>
                <p>Long-course CRT consists of capecitabine and is administered at a dose of
825 mg/m<sup>2</sup> two times per day on radiotherapy days only. A total
dose of 50 Gy will be applied to the primary tumour and surrounding mesorectum, in 25
fractions of 2 Gy, 5 days per week.</p>
                <p>SCRT consists of a total dose of 25 Gy, applied to the primary tumour and surrounding
mesorectum in five fractions of 5 Gy, preferably on five consecutive days.
Radiotherapy for organ preservation is primarily aimed at tumour downstaging and can
therefore be restricted to the peritumoral area including the primary tumour and the
mesorectum resulting in a significant reduction in the irradiated target volume.</p>
              </sec>
              <sec id="s2e">
                <title>Randomisation</title>
                <p>Patients will be randomised on a 1:1:1 basis between standard surgical treatment and
organ-saving treatments. Randomisation will be provided by a computer-generated
program at the University of Birmingham Clinical Trials Units. The randomisation
program will use a minimisation procedure for the following variables:<list list-type="order"><list-item><p>MRI tumour staging (≤T3a N0 V0 and T3b N0 V0) (T3a: tumour extends
&lt;1 mm beyond muscularis propria; T3b: tumour extends
1–5 mm beyond muscularis propria)</p></list-item><list-item><p>country (UK, the Netherlands, Denmark).</p></list-item></list></p>
                <p>Stratification and minimisation will be by T-stage to ensure that the more advanced
tumours are equally represented across treatments; stratification and by country will
be done to account for any bias arising from any possible differences in pretreatment
MRI-based staging assessment.</p>
                <p>To avoid any possibility of the treatment allocation becoming too predictable, a
random factor will be included within the algorithm whereby for a proportion of the
allocations true randomisation will be implemented rather than by using the
minimisation allocation.</p>
              </sec>
              <sec id="s2f">
                <title>Sample size</title>
                <p>No power calculation is provided as the primary objective is to show feasibility of
recruitment. The aim of the present trial is to include four to six patients per
month in order to have a high enough randomisation rate to perform a phase III trial.
For a phase III trial, the primary outcome would be 3-year pelvic failure. The null
hypothesis is that the increase in the rate of pelvic failure at 3 years with organ
preservation compared with standard surgery is less than 7% absolute difference.
Prior data indicate that the pelvic recurrence rate in the radical TME group is 2%.
If the true recurrence rate for patients in an experimental arm is 9% then, using 90%
power and alpha=0.025 (to account for two treatment comparisons) would require 117
patients per treatment arm. Anticipating a 10% dropout rate, we would aim to
randomise 400 participants. The final decision for a phase III sample size will be
taken from information gained during the feasibility study. Data of the phase II
trial will be used for the phase III trial.</p>
              </sec>
              <sec id="s2g">
                <title>Data management</title>
                <p>Case report forms (CRFs) can be entered online at <ext-link ext-link-type="uri" xlink:href="http://www.bctu.bham.ac.uk/STAR-TREC">http://www.bctu.bham.ac.uk/STAR-TREC</ext-link>. Authorised staff at sites will
require an individual secure login username and password to access this online data
entry system. Paper CRFs must be completed, signed/dated and returned to the National
STAR-TREC Trial Office by the investigator or an authorised member of the site
research team. Data reported on each CRF should be consistent with the source data or
the discrepancies should be explained. If information is not known, this must be
clearly indicated on the CRF. All missing and ambiguous data will be queried. All
sections are to be completed.</p>
                <p>Assessment of the health-related quality of life will be done after the patients have
completed a series of questionnaires. The questionnaires European Organisation for
Research and Treatment of Cancer Quality of life questionnaires for colorectal cancer
quality of life questionnaire C30 and CR29 (EORTC QLQL), standardised questionnaire
for use as a measure of health outcome (EQ-5D), Low Anterior Resection Syndrome
(LARS) score and Patient-completed questionnaire for evaluating male/female lower
urinary tract symptoms and impact on quality of life (ICIQ-MLUTS/ICIQ FLUTS)
will be done at three time points, at baseline prior to treatment and at follow-up 12
and 24 months after the start of treatment.</p>
                <p>All trial records must be archived and securely retained for at least 25 years. No
documents will be destroyed without prior approval from the Sponsor, via the central
STAR-TREC trial office. On-site monitoring will be carried out as required following
a risk assessment and as documented in the monitoring plan for each participating
country. Any monitoring activities will be reported to the central STAR-TREC office
and any issues noted will be followed up to resolution. STAR-TREC will also be
centrally monitored; however, additional on-site monitoring may occur if triggered.
Further information regarding data management is provided in the study protocol.</p>
              </sec>
              <sec id="s2h">
                <title>Ethics and dissemination</title>
                <p>The trial will be performed in accordance with the recommendations guiding physicians
in biomedical research involving human subjects, adopted by the 18th World Medical
Association General Assembly, Helsinki, Finland and stated in the respective
participating countries laws governing human research, and Good Clinical Practice.
The medical ethical committees of all the participating countries have approved the
study protocol.</p>
                <p>A meeting will be held after the end of the study to allow discussion of the main
results among the collaborators prior to publication. Results of the primary and
secondary endpoints will be submitted for publication in peer-reviewed journals.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>Discussion</title>
              <p>The TREC and CARTS groups have combined with colleagues in Denmark to design STAR-TREC
study. Phase II data from TREC and CARTS justifies a randomised comparison of standard
radical surgery versus organ-saving treatment using either SCRT or CRT with selective
use of transanal microsurgery based on a radiotherapy response assessment. Organ
preservation is not standard treatment and testing the feasibility is important to
determine the scale of randomised trial that can be performed. The phase II STAR-TREC
study will evaluate the feasibility of accelerating recruitment to an international
three-arm randomised trial.</p>
              <p>The published literature supports use of (chemo)radiotherapy and transanal microsurgery
as an alternative to major surgery for curative treatment of early rectal cancer. To
date, studies have recruited patients who were highly motivated to organ-preserving
treatment. Broader patient populations are yet to be evaluated using these organ-saving
treatments. In addition, the long-term impact of organ-saving treatment after
neoadjuvant treatment, on quality of life and, more importantly, oncological outcome is
unknown. Therefore, these organ-preserving strategies should ideally be compared with
radical TME surgery which represents the current standard of care for patients with
rectal cancer. A randomised trial comparing organ-saving treatment with major surgery
might be practice changing for the treatment of patients with early rectal cancer.</p>
              <p>In addition, while it seems probable that a strategy of organ saving may produce
substantial benefits over conventional radical surgery, the optimum organ-saving
treatment schedule remains unclear. Phase II studies suggest that SCRT may have the
lowest acute toxicity while CRT may achieve the highest cCR rates. Randomisation between
these two strategies with the interval calculated from the start of (chemo)radiotherapy
will give insight in the possible difference in efficacy in these early cancers.
STAR-TREC is, therefore, an international, multicentre, randomised, phase II feasibility
study comprising a 1:1:1 randomisation for eligible subjects with early clinically
localised rectal cancer.</p>
              <p>While published data supports further evaluation of organ saving in patients with
early-stage rectal cancer using either SCRT or CRT followed by transanal microsurgery,
it has also become clear that not all patients require surgery. Watchful waiting after
complete response is being investigated in patients already in need of CRT.<xref rid="R24" ref-type="bibr">24 26 37</xref> Other studies introduce
(chemo)radiation therapy to the treatment regimen in order to facilitate organ
preservation. Current techniques use either SCRT (five fractions of 5 Gy)<xref rid="R40" ref-type="bibr">40 42</xref> or concurrent fluoropyridine-based CRT (25
fractions of 1.8 or 2 Gy).<xref rid="R38" ref-type="bibr">38–40
42</xref> Radiotherapy is routinely followed by TEM, to remove the portion of bowel
wall affected by cancer. However, in a significant proportion of patients, there are no
signs of residual tumour following radiotherapy. This is termed a cCR. These patients
are likely overtreated by routine transanal microsurgery and therefore possibly
subjected to unnecessary surgery-related morbidity. Therefore, patients with a cCR might
be better served by a watchful waiting approach.<xref rid="R44" ref-type="bibr">44</xref></p>
              <p>STAR-TREC study design incorporates several developmental steps, each intended to
further reduce treatment-related side effects associated with organ-preserving
therapy:<list list-type="order"><list-item><p>Modification in the capecitabine dose from 825 mg/m<sup>2</sup> two
times per day for 7 days per week used in CARTS to 825 mg/m<sup>2</sup>
two times per day for 5 days per week.</p></list-item><list-item><p>Use of a smaller radiotherapy volume incorporating only the primary tumour,
rectal wall and mesorectum.</p></list-item><list-item><p>Use of a two-step clinical response assessment tool following (chemo)radiation
so that (1) poor responders are converted to radical TME surgery at the
earliest opportunity while (2) good responders are given more time to determine
if they reach cCR and may avoid transanal microsurgery.</p></list-item><list-item><p>Selective use of transanal microsurgery/TEM for residual mucosal or bowel wall
abnormality suggestive of persisting cancer.</p></list-item><list-item><p>Objective comparison of the efficacy of CRT versus SCRT with similar intervals
between start of radiotherapy and evaluation.</p></list-item></list></p>
              <p>To date, no significant differences are considered for target volume definition for
early or advanced rectal cancers. Target volumes contain at least the primary tumour,
the mesorectal fat, presacral and internal iliac nodes.<xref rid="R45" ref-type="bibr">45</xref> Given that patients in STAR-TREC will be clinically node negative, the
necessity of irradiating presacral and iliac nodes is questionable. Even in the case of
unexpected nodal involvement, the majority of involved lymph nodes will be peritumoral
in the mesorectum, as demonstrated in a series of 121 patients with locally advanced
rectal cancer who underwent CRT.<xref rid="R46" ref-type="bibr">46</xref> The
radiotherapy volume has therefore been reduced to the mesorectal fat only. To ensure
safe introduction of this new technique, strict radiotherapy quality assurance is part
of the protocol.</p>
              <p>STAR-TREC is designed to achieve a recruitment rate that would provide confidence that
extension into a phase III trial is achievable. Further applications for funding, ethics
approval and a substantial protocol amendment would be required for this transition.</p>
            </sec>
            <sec sec-type="conclusions" id="s4">
              <title>Conclusion</title>
              <p>There is an urgent need for a randomised phase III trial to establish the risks and
benefits of organ saving compared with standard TME surgery for early-stage rectal
cancer. STAR-TREC trial builds on experience gained through the TREC and CARTS phase II
studies. STAR-TREC is a multicentre international randomised phase II study designed to
assess the feasibility of recruiting six international patients per month in order to
facilitate the evaluation of TME surgery versus organ-saving strategy preceded by
(chemo)radiation in two different fractionation schedules. The trial aims to improve the
rate of patient recruitment compared with earlier studies and will also introduce a
mesorectal target volume with quality assurance. The ultimate goal of this phase II
feasibility study is to accelerate to a phase III study comparing TME surgery with two
organ-saving treatment regimens.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="d35e664" content-type="local-data">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-019474.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material id="d35e665" content-type="local-data">
                <caption>
                  <title>Author's manuscript</title>
                </caption>
                <media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-019474.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> All collaborators made substantial contributions to the design of the study and/or
were involved in drafting the manuscript. All collaborators read and approved the
final manuscript.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> STAR-TREC is an international study, separately funded in each participating country.
In the UK, this work was supported by Cancer Research UK (C41557/A19393), in the
Netherlands by the Dutch Cancer Society (KWF KUN 2014-7448) and in Denmark by the
Danish Cancer Society (R100-A6747). Contact information of Trial sponsor: Birmingham
Clinical Trials Unit (BCTU), Institute of Applied Health Research, College of Medical
and Dental Sciences, Public Health Building, University of Birmingham, Edgbaston,
Birmingham B15 2TT, UK. Phone: 0121 415 9104; email: STAR-TREC@trials.bham.ac.uk.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Ethics approval:</bold> Commissie mensgebonden onderzoek (CMO).</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; internally peer reviewed.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkin</surname><given-names>WS</given-names></name>,
<name name-style="western"><surname>Cook</surname><given-names>CF</given-names></name>,
<name name-style="western"><surname>Cuzick</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group><article-title>Single flexible sigmoidoscopy screening to prevent colorectal
cancer: baseline findings of a UK multicentre randomised trial</article-title>.
<source>Lancet</source><year>2002</year>;<volume>359</volume>:<fpage>1291</fpage>–<lpage>300</lpage>.
<pub-id pub-id-type="doi">10.1016/S0140-6736(02)08268-5</pub-id><pub-id pub-id-type="pmid">11965274</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><collab>UK Colorectal Cancer Screening Pilot
Group</collab>. <article-title>Results of the first round of a demonstration pilot
of screening for colorectal cancer in the United Kingdom</article-title>.
<source>BMJ</source><year>2004</year>;<volume>329</volume>:<fpage>133</fpage><pub-id pub-id-type="doi">10.1136/bmj.38153.491887.7C</pub-id><pub-id pub-id-type="pmid">15237087</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bentrem</surname><given-names>DJ</given-names></name>,
<name name-style="western"><surname>Okabe</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Wong</surname><given-names>WD</given-names></name>, <etal>et al</etal></person-group><article-title>T1 adenocarcinoma of the rectum: transanal excision or radical
surgery?</article-title><source>Ann Surg</source><year>2005</year>;<volume>242</volume>:<fpage>472</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">16192807</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peeters</surname><given-names>KC</given-names></name>,
<name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Nagtegaal</surname><given-names>ID</given-names></name>, <etal>et al</etal></person-group><article-title>The TME trial after a median follow-up of 6 years: increased local
control but no survival benefit in irradiated patients with resectable rectal
carcinoma</article-title>. <source>Ann Surg</source><year>2007</year>;<volume>246</volume>:<fpage>693</fpage>–<lpage>701</lpage>.
<pub-id pub-id-type="doi">10.1097/01.sla.0000257358.56863.ce</pub-id><pub-id pub-id-type="pmid">17968156</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endreseth</surname><given-names>BH</given-names></name>,
<name name-style="western"><surname>Myrvold</surname><given-names>HE</given-names></name>,
<name name-style="western"><surname>Romundstad</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Transanal excision vs. major surgery for T1 rectal
cancer</article-title>. <source>Dis Colon Rectum</source><year>2005</year>;<volume>48</volume>:<fpage>1380</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1007/s10350-005-0044-6</pub-id><pub-id pub-id-type="pmid">15906120</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bökkerink</surname><given-names>GM</given-names></name>, <name name-style="western"><surname>de
Graaf</surname><given-names>EJ</given-names></name>,
<name name-style="western"><surname>Punt</surname><given-names>CJ</given-names></name>, <etal>et al</etal></person-group><article-title>The CARTS study: Chemoradiation therapy for rectal cancer in the
distal rectum followed by organ-sparing transanal endoscopic
microsurgery</article-title>. <source>BMC Surg</source><year>2011</year>;<volume>11</volume>:<fpage>34</fpage><pub-id pub-id-type="doi">10.1186/1471-2482-11-34</pub-id><pub-id pub-id-type="pmid">22171697</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Homan</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Bökkerink</surname><given-names>GM</given-names></name>,
<name name-style="western"><surname>Aarts</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group><article-title>Variation in circumferential resection margin: Reporting and
involvement in the South-Netherlands</article-title>. <source>Eur J Surg
Oncol</source><year>2015</year>;<volume>41</volume>:<fpage>1485</fpage>–<lpage>92</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejso.2015.07.015</pub-id><pub-id pub-id-type="pmid">26251342</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderin</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Gustafsson</surname><given-names>UO</given-names></name>,
<name name-style="western"><surname>Thorell</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>The effect of diverting stoma on long-term morbidity and risk for
permanent stoma after low anterior resection for rectal cancer</article-title>.
<source>Eur J Surg Oncol</source><year>2016</year>;<volume>42</volume>:<fpage>788</fpage>–<lpage>93</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejso.2016.04.001</pub-id><pub-id pub-id-type="pmid">27132071</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>MJ</given-names></name>,
<name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name>,
<name name-style="western"><surname>Park</surname><given-names>SC</given-names></name>, <etal>et al</etal></person-group><article-title>Risk factors for permanent stoma after rectal cancer surgery with
temporary ileostomy</article-title>. <source>Surgery</source><year>2016</year>;<volume>159</volume>:<fpage>721</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.surg.2015.09.011</pub-id><pub-id pub-id-type="pmid">26490725</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendren</surname><given-names>SK</given-names></name>,
<name name-style="western"><surname>O’Connor</surname><given-names>BI</given-names></name>,
<name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Prevalence of male and female sexual dysfunction is high following
surgery for rectal cancer</article-title>. <source>Ann Surg</source><year>2005</year>;<volume>242</volume>:<fpage>212</fpage>–<lpage>23</lpage>.
<pub-id pub-id-type="doi">10.1097/01.sla.0000171299.43954.ce</pub-id><pub-id pub-id-type="pmid">16041212</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallner</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Lange</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Bonsing</surname><given-names>BA</given-names></name>, <etal>et al</etal></person-group><article-title>Causes of fecal and urinary incontinence after total mesorectal
excision for rectal cancer based on cadaveric surgery: a study from the
Cooperative Clinical Investigators of the Dutch total mesorectal excision
trial</article-title>. <source>J Clin Oncol</source><year>2008</year>;<volume>26</volume>:<fpage>4466</fpage>–<lpage>72</lpage>.
<pub-id pub-id-type="doi">10.1200/JCO.2008.17.3062</pub-id><pub-id pub-id-type="pmid">18802159</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engel</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Kerr</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Schlesinger-Raab</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Quality of life in rectal cancer patients: a four-year prospective
study</article-title>. <source>Ann Surg</source><year>2003</year>;<volume>238</volume>:<fpage>203</fpage>–<lpage>13</lpage>.
<pub-id pub-id-type="doi">10.1097/01.sla.0000080823.38569.b0</pub-id><pub-id pub-id-type="pmid">12894013</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Temple</surname><given-names>LK</given-names></name>,
<name name-style="western"><surname>Bacik</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Savatta</surname><given-names>SG</given-names></name>, <etal>et al</etal></person-group><article-title>The development of a validated instrument to evaluate bowel
function after sphincter-preserving surgery for rectal cancer</article-title>.
<source>Dis Colon Rectum</source><year>2005</year>;<volume>48</volume>:<fpage>1353</fpage>–<lpage>65</lpage>.
<pub-id pub-id-type="doi">10.1007/s10350-004-0942-z</pub-id><pub-id pub-id-type="pmid">15868235</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lange</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Maas</surname><given-names>CP</given-names></name>, <etal>et al</etal></person-group><article-title>Risk factors for sexual dysfunction after rectal cancer
treatment</article-title>. <source>Eur J Cancer</source><year>2009</year>;<volume>45</volume>:<fpage>1578</fpage>–<lpage>88</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ejca.2008.12.014</pub-id><pub-id pub-id-type="pmid">19147343</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Kapiteijn</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van de
Velde</surname><given-names>CJ</given-names></name>, <etal>et al</etal></person-group><article-title>Acute side effects and complications after short-term preoperative
radiotherapy combined with total mesorectal excision in primary rectal cancer:
report of a multicenter randomized trial</article-title>. <source>J Clin
Oncol</source><year>2002</year>;<volume>20</volume>:<fpage>817</fpage>–<lpage>25</lpage>.
<pub-id pub-id-type="doi">10.1200/JCO.2002.20.3.817</pub-id><pub-id pub-id-type="pmid">11821466</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grumann</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Noack</surname><given-names>EM</given-names></name>,
<name name-style="western"><surname>Hoffmann</surname><given-names>IA</given-names></name>, <etal>et al</etal></person-group><article-title>Comparison of quality of life in patients undergoing
abdominoperineal extirpation or anterior resection for rectal
cancer</article-title>. <source>Ann Surg</source><year>2001</year>;<volume>233</volume>:<fpage>149</fpage>–<lpage>56</lpage>.
<pub-id pub-id-type="doi">10.1097/00000658-200102000-00001</pub-id><pub-id pub-id-type="pmid">11176118</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>TR</given-names></name>,
<name name-style="western"><surname>Alexander</surname><given-names>DJ</given-names></name></person-group><article-title>Clinical and non-clinical factors influencing postoperative
health-related quality of life in patients with colorectal cancer</article-title>.
<source>Br J Surg</source><year>2008</year>;<volume>95</volume>:<fpage>1408</fpage>–<lpage>15</lpage>.
<pub-id pub-id-type="doi">10.1002/bjs.6376</pub-id><pub-id pub-id-type="pmid">18844250</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephens</surname><given-names>RJ</given-names></name>,
<name name-style="western"><surname>Thompson</surname><given-names>LC</given-names></name>,
<name name-style="western"><surname>Quirke</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Impact of short-course preoperative radiotherapy for rectal cancer
on patients' quality of life: data from the Medical Research Council CR07/National
Cancer Institute of Canada Clinical Trials Group C016 randomized clinical
trial</article-title>. <source>J Clin Oncol</source><year>2010</year>;<volume>28</volume>:<fpage>4233</fpage>–<lpage>9</lpage>.
<pub-id pub-id-type="doi">10.1200/JCO.2009.26.5264</pub-id><pub-id pub-id-type="pmid">20585099</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiltink</surname><given-names>LM</given-names></name>,
<name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Meershoek-Klein Kranenbarg</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group><article-title>A comprehensive longitudinal overview of health-related quality of
life and symptoms after treatment for rectal cancer in the TME
trial</article-title>. <source>Acta Oncol</source><year>2016</year>;<volume>55</volume>:<fpage>502</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.3109/0284186X.2015.1088171</pub-id><pub-id pub-id-type="pmid">26406287</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapiteijn</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Nagtegaal</surname><given-names>ID</given-names></name>, <etal>et al</etal></person-group><article-title>Preoperative radiotherapy combined with total mesorectal excision
for resectable rectal cancer</article-title>. <source>N Engl J Med</source><year>2001</year>;<volume>345</volume>:<fpage>638</fpage>–<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1056/NEJMoa010580</pub-id><pub-id pub-id-type="pmid">11547717</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tekkis</surname><given-names>PP</given-names></name>,
<name name-style="western"><surname>Poloniecki</surname><given-names>JD</given-names></name>,
<name name-style="western"><surname>Thompson</surname><given-names>MR</given-names></name>, <etal>et al</etal></person-group><article-title>Operative mortality in colorectal cancer: prospective national
study</article-title>. <source>BMJ</source><year>2003</year>;<volume>327</volume>:<fpage>1196</fpage>–<lpage>201</lpage>.
<pub-id pub-id-type="doi">10.1136/bmj.327.7425.1196</pub-id><pub-id pub-id-type="pmid">14630754</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bos</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>van
Erning</surname><given-names>FN</given-names></name>,
<name name-style="western"><surname>Elferink</surname><given-names>MA</given-names></name>, <etal>et al</etal></person-group><article-title>No Difference in Overall Survival Between Hospital Volumes for
Patients With Colorectal Cancer in The Netherlands</article-title>. <source>Dis
Colon Rectum</source><year>2016</year>;<volume>59</volume>:<fpage>943</fpage>–<lpage>52</lpage>.
<pub-id pub-id-type="doi">10.1097/DCR.0000000000000660</pub-id><pub-id pub-id-type="pmid">27602925</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habr-Gama</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Gama-Rodrigues</surname><given-names>J</given-names></name>, <name name-style="western"><surname>São
Julião</surname><given-names>GP</given-names></name>, <etal>et al</etal></person-group><article-title>Local recurrence after complete clinical response and watch and
wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy
on local disease control</article-title>. <source>Int J Radiat Oncol Biol
Phys</source><year>2014</year>;<volume>88</volume>:<fpage>822</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.12.012</pub-id><pub-id pub-id-type="pmid">24495589</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habr-Gama</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Perez</surname><given-names>RO</given-names></name>,
<name name-style="western"><surname>Nadalin</surname><given-names>W</given-names></name>, <etal>et al</etal></person-group><article-title>Operative versus nonoperative treatment for stage 0 distal rectal
cancer following chemoradiation therapy</article-title>. <source>Trans Meet Am
Surg Assoc Am Surg Assoc</source><year>2004</year>;<volume>CXXII</volume>:<fpage>309</fpage>–<lpage>16</lpage>.
<pub-id pub-id-type="doi">10.1097/01.sla.0000141194.27992.32</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maas</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Beets-Tan</surname><given-names>RG</given-names></name>,
<name name-style="western"><surname>Lambregts</surname><given-names>DM</given-names></name>, <etal>et al</etal></person-group><article-title>Wait-and-see policy for clinical complete responders after
chemoradiation for rectal cancer</article-title>. <source>J Clin Oncol</source><year>2011</year>;<volume>29</volume>:<fpage>4633</fpage>–<lpage>40</lpage>.
<pub-id pub-id-type="doi">10.1200/JCO.2011.37.7176</pub-id><pub-id pub-id-type="pmid">22067400</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appelt</surname><given-names>AL</given-names></name>,
<name name-style="western"><surname>Pløen</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Harling</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group><article-title>High-dose chemoradiotherapy and watchful waiting for distal rectal
cancer: a prospective observational study</article-title>. <source>Lancet
Oncol</source><year>2015</year>;<volume>16</volume>:<fpage>919</fpage>–<lpage>27</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(15)00120-5</pub-id><pub-id pub-id-type="pmid">26156652</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glynne-Jones</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Livingstone</surname><given-names>JI</given-names></name>, <etal>et al</etal></person-group><article-title>Complete clinical response after preoperative chemoradiation in
rectal cancer: is a "wait and see" policy justified?</article-title><source>Dis Colon Rectum</source><year>2008</year>;<volume>51</volume>:<fpage>10</fpage>–<lpage>20</lpage>.
<pub-id pub-id-type="doi">10.1007/s10350-007-9080-8</pub-id><pub-id pub-id-type="pmid">18043968</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Renehan</surname><given-names>AG</given-names></name>,
<name name-style="western"><surname>Malcomson</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Emsley</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group><article-title>Watch-and-wait approach versus surgical resection after
chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a
propensity-score matched cohort analysis</article-title>. <source>Lancet
Oncol</source><year>2016</year>;<volume>17</volume>:<fpage>174</fpage>–<lpage>83</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(15)00467-2</pub-id><pub-id pub-id-type="pmid">26705854</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Aguilar</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Chow</surname><given-names>OS</given-names></name>,
<name name-style="western"><surname>Smith</surname><given-names>DD</given-names></name>, <etal>et al</etal></person-group><article-title>Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in
locally advanced rectal cancer: a multicentre, phase 2 trial</article-title>.
<source>Lancet Oncol</source><year>2015</year>;<volume>16</volume>:<fpage>957</fpage>–<lpage>66</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(15)00004-2</pub-id><pub-id pub-id-type="pmid">26187751</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bach</surname><given-names>SP</given-names></name>,
<name name-style="western"><surname>Hill</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Monson</surname><given-names>JR</given-names></name>, <etal>et al</etal></person-group><article-title>A predictive model for local recurrence after transanal endoscopic
microsurgery for rectal cancer</article-title>. <source>Br J Surg</source><year>2009</year>;<volume>96</volume>:<fpage>280</fpage>–<lpage>90</lpage>.
<pub-id pub-id-type="doi">10.1002/bjs.6456</pub-id><pub-id pub-id-type="pmid">19224520</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cataldo</surname><given-names>PA</given-names></name>,
<name name-style="western"><surname>O’Brien</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Osler</surname><given-names>T</given-names></name></person-group><article-title>Transanal endoscopic microsurgery: a prospective evaluation of
functional results</article-title>. <source>Dis Colon Rectum</source><year>2005</year>;<volume>48</volume>:<fpage>1366</fpage>–<lpage>71</lpage>.
<pub-id pub-id-type="doi">10.1007/s10350-005-0031-y</pub-id><pub-id pub-id-type="pmid">15933798</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Restivo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Zorcolo</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>D’Alia</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group><article-title>Risk of complications and long-term functional alterations after
local excision of rectal tumors with transanal endoscopic microsurgery
(TEM)</article-title>. <source>Int J Colorectal Dis</source><year>2016</year>;<volume>31</volume>:<fpage>257</fpage>–<lpage>66</lpage>.
<pub-id pub-id-type="doi">10.1007/s00384-015-2371-y</pub-id><pub-id pub-id-type="pmid">26298182</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>AS</given-names></name>,
<name name-style="western"><surname>Coralic</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Kelleher</surname><given-names>DC</given-names></name>, <etal>et al</etal></person-group><article-title>Complications of transanal endoscopic microsurgery are rare and
minor: a single institution’s analysis and comparison to existing
data</article-title>. <source>Dis Colon Rectum</source><year>2013</year>;<volume>56</volume>:<fpage>295</fpage>–<lpage>300</lpage>.
<pub-id pub-id-type="doi">10.1097/DCR.0b013e31827163f7</pub-id><pub-id pub-id-type="pmid">23392142</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>You</surname><given-names>YN</given-names></name>,
<name name-style="western"><surname>Baxter</surname><given-names>NN</given-names></name>,
<name name-style="western"><surname>Stewart</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Is the increasing rate of local excision for stage I rectal cancer
in the United States justified?: a nationwide cohort study from the National
Cancer Database</article-title>. <source>Ann Surg</source><year>2007</year>;<volume>245</volume>:<fpage>726</fpage>–<lpage>33</lpage>.
<pub-id pub-id-type="doi">10.1097/01.sla.0000252590.95116.4f</pub-id><pub-id pub-id-type="pmid">17457165</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Aguilar</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Mellgren</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Sirivongs</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Local excision of rectal cancer without adjuvant therapy: a word of
caution</article-title>. <source>Ann Surg</source><year>2000</year>;<volume>231</volume>:<fpage>345</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">10714627</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricciardi</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Madoff</surname><given-names>RD</given-names></name>,
<name name-style="western"><surname>Rothenberger</surname><given-names>DA</given-names></name>, <etal>et al</etal></person-group><article-title>Population-based analyses of lymph node metastases in colorectal
cancer</article-title>. <source>Clin Gastroenterol Hepatol</source><year>2006</year>;<volume>4</volume>:<fpage>1522</fpage>–<lpage>7</lpage>.
<pub-id pub-id-type="doi">10.1016/j.cgh.2006.07.016</pub-id><pub-id pub-id-type="pmid">16979956</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martens</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Maas</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Heijnen</surname><given-names>LA</given-names></name>, <etal>et al</etal></person-group><article-title>Long-term Outcome of an Organ Preservation Program After
Neoadjuvant Treatment for Rectal Cancer</article-title>. <source>J Natl Cancer
Inst</source><year>2016</year>;<volume>108</volume>:<fpage>djw171</fpage><pub-id pub-id-type="doi">10.1093/jnci/djw171</pub-id><pub-id pub-id-type="pmid">27509881</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Gijn</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name>,
<name name-style="western"><surname>Nagtegaal</surname><given-names>ID</given-names></name>, <etal>et al</etal></person-group><article-title>Preoperative radiotherapy combined with total mesorectal excision
for resectable rectal cancer: 12-year follow-up of the multicentre, randomised
controlled TME trial</article-title>. <source>Lancet Oncol</source><year>2011</year>;<volume>12</volume>:<fpage>575</fpage>–<lpage>82</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(11)70097-3</pub-id><pub-id pub-id-type="pmid">21596621</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lezoche</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Baldarelli</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Lezoche</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group><article-title>Randomized clinical trial of endoluminal locoregional resection
versus laparoscopic total mesorectal excision for T2 rectal cancer after
neoadjuvant therapy</article-title>. <source>Br J Surg</source><year>2012</year>;<volume>99</volume>:<fpage>1211</fpage>–<lpage>8</lpage>.
<pub-id pub-id-type="doi">10.1002/bjs.8821</pub-id><pub-id pub-id-type="pmid">22864880</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bujko</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Richter</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Smith</surname><given-names>FM</given-names></name>, <etal>et al</etal></person-group><article-title>Preoperative radiotherapy and local excision of rectal cancer with
immediate radical re-operation for poor responders: a prospective multicentre
study</article-title>. <source>Radiother Oncol</source><year>2013</year>;<volume>106</volume>:<fpage>198</fpage>–<lpage>205</lpage>.
<pub-id pub-id-type="doi">10.1016/j.radonc.2012.12.005</pub-id><pub-id pub-id-type="pmid">23333016</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verseveld</surname><given-names>M</given-names></name>, <name name-style="western"><surname>de
Graaf</surname><given-names>EJ</given-names></name>,
<name name-style="western"><surname>Verhoef</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group><article-title>Chemoradiation therapy for rectal cancer in the distal rectum
followed by organ-sparing transanal endoscopic microsurgery (CARTS
study)</article-title>. <source>Br J Surg</source><year>2015</year>;<volume>102</volume>:<fpage>853</fpage>–<lpage>60</lpage>.
<pub-id pub-id-type="doi">10.1002/bjs.9809</pub-id><pub-id pub-id-type="pmid">25847025</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smart</surname><given-names>CJ</given-names></name>,
<name name-style="western"><surname>Korsgen</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Hill</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group><article-title>Multicentre study of short-course radiotherapy and transanal
endoscopic microsurgery for early rectal cancer</article-title>. <source>Br J
Surg</source><year>2016</year>;<volume>103</volume>:<fpage>1069</fpage>–<lpage>75</lpage>.
<pub-id pub-id-type="doi">10.1002/bjs.10171</pub-id><pub-id pub-id-type="pmid">27146472</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Aguilar</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Renfro</surname><given-names>LA</given-names></name>,
<name name-style="western"><surname>Chow</surname><given-names>OS</given-names></name>, <etal>et al</etal></person-group><article-title>Organ preservation for clinical T2N0 distal rectal cancer using
neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an
open-label, single-arm, multi-institutional, phase 2 trial</article-title>.
<source>Lancet Oncol</source><year>2015</year>;<volume>16</volume>:<fpage>1537</fpage>–<lpage>46</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(15)00215-6</pub-id><pub-id pub-id-type="pmid">26474521</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marijnen</surname><given-names>CA</given-names></name></person-group><article-title>Organ preservation in rectal cancer: have all questions been
answered?</article-title><source>Lancet Oncol</source><year>2015</year>;<volume>16</volume>:<fpage>e13</fpage>–<lpage>e22</lpage>.
<pub-id pub-id-type="doi">10.1016/S1470-2045(14)70398-5</pub-id><pub-id pub-id-type="pmid">25638548</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valentini</surname><given-names>V</given-names></name>,
<name name-style="western"><surname>Gambacorta</surname><given-names>MA</given-names></name>,
<name name-style="western"><surname>Barbaro</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group><article-title>International consensus guidelines on Clinical Target Volume
delineation in rectal cancer</article-title>. <source>Radiother Oncol</source><year>2016</year>;<volume>120</volume>:<fpage>195</fpage>–<lpage>201</lpage>.
<pub-id pub-id-type="doi">10.1016/j.radonc.2016.07.017</pub-id><pub-id pub-id-type="pmid">27528121</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leibold</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Shia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ruo</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group><article-title>Prognostic implications of the distribution of lymph node
metastases in rectal cancer after neoadjuvant chemoradiotherapy</article-title>.
<source>J Clin Oncol</source><year>2008</year>;<volume>26</volume>:<fpage>2106</fpage>–<lpage>11</lpage>.
<pub-id pub-id-type="doi">10.1200/JCO.2007.12.7704</pub-id><pub-id pub-id-type="pmid">18362367</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
